Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5415924 | 0.89 | PPARG (0.49) | PTGDR2MAPTL3MBTL1GLAMEN1 | |
| SCHEMBL3271015 | 0.84 | LMNA (0.47) | PTGDR2MAPTMEN1KMT2APTGDR | |
| SCHEMBL3684907 | 0.83 | ALDH1A1 (0.49) | MAPTL3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL5404749 | 0.81 | TSHR (0.58) | PTGDR2MAPTL3MBTL1GLATSHR | |
| SCHEMBL4655073 | 0.81 | ELANE (0.56) | PTGDR2MAPTL3MBTL1GLAMEN1 | |
| SCHEMBL16342279 | 0.81 | PTGDR2 (0.60) | PTGDR2MAPTL3MBTL1GLAMEN1 | |
| SCHEMBL2823002 | 0.81 | PPARD (0.52) | PTGDR2L3MBTL1GLATDP1TSHR | |
| SCHEMBL14340636 | 0.80 | MAPT (0.77) | PTGDR2MAPTTDP1PTGDRTSHR | |
| SCHEMBL3532387 | 0.80 | POLB (0.62) | PTGDR2L3MBTL1GLAMEN1KMT2A | |
| SCHEMBL5699506 | 0.80 | PTGDR2 (0.77) | PTGDR2MAPTL3MBTL1GLATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558572-B1 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-06-30 | — | — | EP | disclosed |
| US-7598266-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090054479-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | CONNER SCOTT EUGENE | 2009-02-26 | — | — | US | disclosed |
| US-7449468-B2 | Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-7384965-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-20070225294-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | BANKER PIERETTE | 2007-09-27 | — | — | US | disclosed |
| US-7229998-B2 | Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070072871-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | BANKER PIERETTE | 2007-03-29 | — | — | US | disclosed |
| US-7129268-B2 | Peroxisome proliferator activated receptor-active arylene acetic acid derivatives | NOVO NORDISK A/S (DK) | 2006-10-31 | — | — | US | disclosed |
| US-20060205744-A1 | Fused heterocyclic derivatives as ppar modulators | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2006-09-14 | — | — | US | disclosed |
| EP-1558572-A2 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | NOVO NORDISK A/S (DK) | 2005-08-03 | — | — | EP | disclosed |
| EP-1349843-B1 | THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | SMITHKLINE BEECHAM CORP (US) | 2005-04-20 | — | — | EP | disclosed |
| US-20050070583-A1 | Novel compounds, their preparation and use | VTVX HOLDINGS II LLC | 2005-03-31 | — | — | US | disclosed |
| WO-2004037776-A2 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | WO | disclosed |
| US-20040077659-A1 | Method for treating ppar gamma mediated diseases or conditions | SMITHKLINE BEECHAM CORPORATION | 2004-04-22 | — | — | US | disclosed |
| US-20040072838-A1 | Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors | SMITHKLINE BEECHAM CORPORATION | 2004-04-15 | — | — | US | disclosed |
| EP-1368011-A1 | METHOD FOR TREATING PPAR GAMMA MEDIATED DISEASES | SmithKline Beecham Corporation (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002067912-A2 | METHOD FOR TREATING PPAR GAMMA MEDIATED DISEASES OR CONDITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205744-A1 | Fused heterocyclic derivatives as ppar modulators | PPARA, PPARG, PPARD | PTGDR2 319/4885MAPT 4866/4885L3MBTL1 4513/4885 |
| US-20050070583-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | PTGDR2 65/4885MAPT 3498/4885L3MBTL1 4857/4885 |
| US-20070072871-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | PPARD, PPARG, PPARA | PTGDR2 365/4885MAPT 4713/4885L3MBTL1 4484/4885 |
| US-20070225294-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | GPR119, PPARA, PPARG | PTGDR2 412/4885MAPT 4805/4885L3MBTL1 2460/4885 |
| US-20040077659-A1 | Method for treating ppar gamma mediated diseases or conditions | PPARG, PPARA, PPARD | PTGDR2 201/4885MAPT 3868/4885L3MBTL1 3453/4885 |
| US-20040072838-A1 | Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors | PPARA, PPARG, PPARD | PTGDR2 999/4885MAPT 4132/4885L3MBTL1 3527/4885 |
| US-20090054479-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | PPARA, PPARG, PPARD | PTGDR2 284/4885MAPT 4863/4885L3MBTL1 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.